Marks 5th Sales Contract to Nigeria in the Past Six Months
Nov 02, 2012 (Marketwire via COMTEX) --Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold three more Quantum Sniffer™ QS-H150 handheld explosives trace detectors to a corporate customer for critical infrastructure protection in Nigeria.
This marks the fifth sales contract in the African nation in the past six months. This was the second sale made by Implant Sciences' in-country Nigerian distributor, AC Belgrave. Recent sales in Nigeria have included deployment for airline catering and hotels.
"We've experienced a rapid expansion in our sales since the first QS-H150 was sold into the country just months ago. The unfortunate growing threat from terrorist groups has created a need for high security at commercial and governmental buildings. The Quantum Sniffer can play a growing role in this security environment," stated Darryl Jones, Implant Sciences' Vice President of Sales and Marketing.
"In a similar trend to what we have experienced in China, initial sales of our Quantum Sniffers are quickly generating a positive reputation for reliability and accuracy in Africa. Thanks to our dedicated local distributors' superior sales and customer service capabilities, we are able to deliver high-quality, high-performance, made in the U.S.A. equipment to our international customers. We anticipate continued growth in the African continent," added Glenn D. Bolduc, Implant Sciences' President and CEO.
About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.
About Quantum Sniffer™ QS-B220 Desktop Explosives & Drugs Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation